Provention Bio Inc. (PRVB) Expands Leadership Team
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Provention Bio Announces Leadership Team Expansion
December 20, 2021 7:34 AM ESTRED BANK, N.J., Dec. 20, 2021 /PRNewswire/ -- December 20, 2021 Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has appointed Christina Yi as Chief Operations Officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality. These new leadership appointments reinforce Proventions' commitment to quality manufacturing and supply chain excellence and investment in human capital, talent acquisition and cultural alignment with the Company's... More
